These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10602690)

  • 1. Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397).
    Kawamoto H; Ozaki S; Itoh Y; Miyaji M; Arai S; Nakashima H; Kato T; Ohta H; Iwasawa Y
    J Med Chem; 1999 Dec; 42(25):5061-3. PubMed ID: 10602690
    [No Abstract]   [Full Text] [Related]  

  • 2. A new synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay.
    Smith ED; Ariane Vinson N; Zhong D; Berrang BD; Catanzaro JL; Thomas JB; Navarro HA; Gilmour BP; Deschamps J; Carroll FI
    Bioorg Med Chem; 2008 Jan; 16(2):822-9. PubMed ID: 17976996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORL1) antagonist: J-113397.
    Ozaki S; Kawamoto H; Itoh Y; Miyaji M; Iwasawa Y; Ohta H
    Eur J Pharmacol; 2000 Jan; 387(3):R17-8. PubMed ID: 10650183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist.
    Ozaki S; Kawamoto H; Itoh Y; Miyaji M; Azuma T; Ichikawa D; Nambu H; Iguchi T; Iwasawa Y; Ohta H
    Eur J Pharmacol; 2000 Aug; 402(1-2):45-53. PubMed ID: 10940356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new synthetic approach to 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-benzimidazol-2-one(J-113397), the first non-peptide ORL-1 receptor antagonist.
    De Risi C; Piero Pollini G; Trapella C; Peretto I; Ronzoni S; Giardina GA
    Bioorg Med Chem; 2001 Jul; 9(7):1871-7. PubMed ID: 11425589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-[11C]ethyl-1,3-dihydro-2H-benzimidazol-2-one as a brain ORL1 receptor imaging agent for positron emission tomography.
    Ogawa M; Hatano K; Kawasumi Y; Ishiwata K; Kawamura K; Ozaki S; Ito K
    Nucl Med Biol; 2003 Jan; 30(1):51-9. PubMed ID: 12493543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nociceptin inhibits capsaicin-induced bronchoconstriction in isolated guinea pig lung.
    Corboz MR; Rivelli MA; Egan RW; Tulshian D; Matasi J; Fawzi AB; Benbow L; Smith-Torhan A; Zhang H; Hey JA
    Eur J Pharmacol; 2000 Aug; 402(1-2):171-9. PubMed ID: 10940371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Signaling and Structure-Activity Analyses Demonstrate Functional Selectivity at the Nociceptin/Orphanin FQ Opioid Receptor.
    Chang SD; Mascarella SW; Spangler SM; Gurevich VV; Navarro HA; Carroll FI; Bruchas MR
    Mol Pharmacol; 2015 Sep; 88(3):502-11. PubMed ID: 26134494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitussive action of nociceptin in the cat.
    Bolser DC; McLeod RL; Tulshian DB; Hey JA
    Eur J Pharmacol; 2001 Oct; 430(1):107-11. PubMed ID: 11698070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the ORL1 receptor-mediated inhibition of noradrenaline release in human and rat neocortical slices.
    Rominger A; Förster S; Zentner J; Dooley DJ; McKnight AT; Feuerstein TJ; Jackisch R; Vlaskovska M
    Br J Pharmacol; 2002 Feb; 135(3):800-6. PubMed ID: 11834628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of an orally active opioid receptor-like 1 (ORL1) receptor antagonist 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine as clinical candidate.
    Satoh A; Sagara T; Sakoh H; Hashimoto M; Nakashima H; Kato T; Goto Y; Mizutani S; Azuma-Kanoh T; Tani T; Okuda S; Okamoto O; Ozaki S; Iwasawa Y; Ohta H; Kawamoto H
    J Med Chem; 2009 Jul; 52(14):4091-4. PubMed ID: 19537798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
    Viaro R; Marti M; Morari M
    Exp Neurol; 2010 Jun; 223(2):473-84. PubMed ID: 20122926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
    Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
    J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-regulated internalization of the opioid receptor-like 1: a confocal study.
    Corbani M; Gonindard C; Meunier JC
    Endocrinology; 2004 Jun; 145(6):2876-85. PubMed ID: 15016723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice.
    Volta M; Mabrouk OS; Bido S; Marti M; Morari M
    J Neurochem; 2010 Dec; 115(6):1543-55. PubMed ID: 20950413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of amygdaloid nuclei in the anxiolytic-like effect of nociceptin/orphanin FQ in rats.
    Uchiyama H; Toda A; Hiranita T; Watanabe S; Eyanagi R
    Neurosci Lett; 2008 Jan; 431(1):66-70. PubMed ID: 18166271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance.
    Chung S; Pohl S; Zeng J; Civelli O; Reinscheid RK
    J Pharmacol Exp Ther; 2006 Jul; 318(1):262-7. PubMed ID: 16595734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel benzimidazole series of potent and selective ORL1 antagonists.
    Okamoto O; Kobayashi K; Kawamoto H; Ito S; Satoh A; Kato T; Yamamoto I; Mizutani S; Hashimoto M; Shimizu A; Sakoh H; Nagatomi Y; Iwasawa Y; Takahashi H; Ishii Y; Ozaki S; Ohta H
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3278-81. PubMed ID: 18468891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
    Thomas JB; Atkinson RN; Vinson NA; Catanzaro JL; Perretta CL; Fix SE; Mascarella SW; Rothman RB; Xu H; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 2003 Jul; 46(14):3127-37. PubMed ID: 12825951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine.
    Thomas JB; Fall MJ; Cooper JB; Rothman RB; Mascarella SW; Xu H; Partilla JS; Dersch CM; McCullough KB; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 1998 Dec; 41(26):5188-97. PubMed ID: 9857089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.